Twist Bioscience TWST
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Twist Bioscience (TWST) Core Market Data and Business Metrics
Latest Closing Price
$38.21Price-Earnings Ratio
-11.30Total Outstanding Shares
59.65 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
681 Gateway Blvd., South San Francisco, CA, 94080
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,436,284 Shares | 6.15 | 3/14/2025 | 8,830,123 Shares |
| 993,849 Shares | 9.36 | 2/28/2025 | 9,299,111 Shares |
| 1,052,599 Shares | 8.75 | 2/14/2025 | 9,215,413 Shares |
| 754,312 Shares | 11.45 | 1/31/2025 | 8,636,527 Shares |
| 684,059 Shares | 13.41 | 1/15/2025 | 9,175,202 Shares |
| 812,678 Shares | 10.7 | 12/31/2024 | 8,697,864 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $-45.01 Million |
| Net Cash Flow | $-45.06 Million |
| Exchange Gains/Losses | $-43,000 |
| Net Cash Flow From Operating Activities, Continuing | $-62.55 Million |
| Net Cash Flow From Investing Activities, Continuing | $-8.77 Million |
| Net Cash Flow From Financing Activities, Continuing | $26.31 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Benefits Costs and Expenses | $526.96 Million |
| Basic Earnings Per Share | $-3.38 |
| Net Income/Loss Available To Common Stockholders, Basic | $-197.31 Million |
| Operating Expenses | $355.72 Million |
| Costs And Expenses | $538.69 Million |
| Revenues | $330.19 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-197.40 Million |
| Comprehensive Income/Loss | $-197.40 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-84,000 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Assets | $608.58 Million |
| Fixed Assets | $100.67 Million |
| Inventory | $23.52 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Wages | $21.74 Million |
| Equity Attributable To Parent | $455.94 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||